Article Sidebar

pdf
Date Published: 11/04/2025
Abstract Views: 57
Views pdf: 31
DOI: https://doi.org/10.51298/vmj.v548i2.13420
Issue
Vol. 548 No. 2 (2025)
Section
Các bài báo
How to Cite
Đỗ, A. T., Trần, M. P., Vũ, H. T., & Nguyễn, T. V. (2025). RESULTS OF TREATMENT ADVANCED STAGE BILIARY TRACT CANCERS BY REGIMEN GEMCITABINE-OXALIPLATIN-BEVACIZUMAB AT K HOSPITAL. Vietnam Medical Journal, 548(2). https://doi.org/10.51298/vmj.v548i2.13420

RESULTS OF TREATMENT ADVANCED STAGE BILIARY TRACT CANCERS BY REGIMEN GEMCITABINE-OXALIPLATIN-BEVACIZUMAB AT K HOSPITAL

Anh Tú Đỗ, Mai Phương Trần, Huyền Trang Vũ, Thị Vân Nguyễn

Main Article Content

Abstract

Objectives: Evaluate the results of treatment advanced stage biliary tract cancers by regimen gemcitabine-oxaliplatin-bevacizumab at K hospital. Patients and Methods: 32 patients biliary tract cancers at advanced stage was treated with regimen gemcitabine-oxaliplatin-bevacizumab at K hospital from January 2021 to June 2024. Results: Male/female =1.67/1. Recurrent disease in 5 and metastastic disease in 26, locally advanced stage in 1. Main reason go to hospital is abdominal pain. Elevated CA19.9 in 59.4%. The overall response rate was 41.9% and disease control rate was 67.7%. Median PFS was 5.5 months. Bevacizumab-induced toxicity occurred in 25% of cases, and 3 patients had to permanently discontinue treatment. Conclusion: Treatment advanced stage biliary tract cancers by regimen gemcitabine-oxaliplatin-bevacizumab have both response rate and disease control rate high and prolong progression free survival.

Article Details

Keywords

biliary tract cancers, bevacizumab.

References

Banales, J. M. et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 13, 261–280 (2016).
2. Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA. Cancer J. Clin. 73, 17–48 (2023).
3. Hida, Y. et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res. 19, 2257–2260 (1999).
4. Bréchon, M. et al. Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. Invest. New Drugs 36, 156–162 (2018).
5. Kirstein, M. M. & Vogel, A. Epidemiology and Risk Factors of Cholangiocarcinoma. Viszeralmedizin 32, 395–400 (2016).
6. Nịnh Thị Thảo. Kết quả hóa trị phác đồ gemcitabine-cisplatin trong ung thư đường mật giai đoạn muộn. Luận văn thạc sĩ đại học Y Hà Nội (2021).
7. Zhu, A. X. et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 11, 48–54 (2010).
8. Pei, S.-N. et al. A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study. Cancers 13, 3831 (2021).
9. Park, H. S. et al. Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 49, 1127–1139 (2017).